PTC Therapeutics, Inc. Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)
PTC Therapeutics, Inc. (PTCT) reported Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) of $159.50 million for the 3-month period ending 2024-12-31, per its 10-K filed 2025-02-27.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill · last filed 2026-02-19
- PTC Therapeutics, Inc. impairment of intangible assets, indefinite-lived (excluding goodwill) for the quarter ending 2024-12-31 was $159.50M.
- PTC Therapeutics, Inc. impairment of intangible assets, indefinite-lived (excluding goodwill) for the quarter ending 2023-12-31 was $0.00.
- PTC Therapeutics, Inc. impairment of intangible assets, indefinite-lived (excluding goodwill) for the quarter ending 2023-09-30 was $0.00.
- PTC Therapeutics, Inc. impairment of intangible assets, indefinite-lived (excluding goodwill) for the quarter ending 2023-06-30 was $217.80M.
- PTC Therapeutics, Inc. impairment of intangible assets, indefinite-lived (excluding goodwill) for fiscal 2024 was $159.55M, a 26.75% decline from fiscal 2023.
- PTC Therapeutics, Inc. impairment of intangible assets, indefinite-lived (excluding goodwill) for fiscal 2023 was $217.80M, a 552.41% increase from fiscal 2022.
- PTC Therapeutics, Inc. impairment of intangible assets, indefinite-lived (excluding goodwill) for fiscal 2022 was $33.38M.
- PTC Therapeutics, Inc. impairment of intangible assets, indefinite-lived (excluding goodwill) for fiscal 2021 was $0.00.
| Period end | Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) 3 month | Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) 6 month | Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) 9 month | Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) 12 month |
|---|---|---|---|---|
| 2024-12-31 | $159.50M 10-K · filed 2025-02-27 | $159.55M 10-K · filed 2026-02-19 | ||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $0.00 derived: sum of 2 quarters · filed 2026-02-19 | $217.80M derived: sum of 3 quarters · filed 2026-02-19 | $217.80M 10-K · filed 2026-02-19 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $217.80M derived: sum of 2 quarters · filed 2024-11-07 | $217.80M 10-Q · filed 2024-11-07 | |
| 2023-06-30 | $217.80M 10-Q · filed 2024-08-08 | $217.80M 10-Q · filed 2024-08-08 | ||
| 2022-12-31 | $33.38M 10-K · filed 2025-02-27 | |||
| 2021-12-31 | $0.00 10-K · filed 2022-02-22 | |||
| 2020-12-31 | $0.00 10-K · filed 2021-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |